Condition: Lung Cancer · NSCLC · NSCLC Stage IV · Sponsor: Jun Zhang, MD, PhD
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
This description comes directly from the study's public registry record.
Darlene Kocher · 9135887132 · dkocher@kumc.edu
Jonathon Barnette · 9135887132 · jbarnette@kumc.edu
Always discuss trial participation with your own doctor first.
| The University of Kansas Cancer Center (KUCC) | Fairway, Kansas, United States | Recruiting |
| The University of Kansas Cancer Center, Westwood Campus | Kansas City, Kansas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05332925